Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis
详细信息 查看全文
- 作者：Sonia Morales-Santanaa ; b ; c ; Adolfo Dí ; ez-Pé ; rezb ; d ; José ; M. Olmosb ; e ; Xavier Nogué ; sb ; d ; Manuel Sosaf ; Manuel Dí ; az-Curielb ; g ; José ; L. Pé ; rez-Castrilló ; nb ; h ; Ramó ; n Pé ; rez-Canob ; i ; Antonio Torrijosb ; j ; Esteban Jodarb ; k ; Luis Del Riob ; l ; José ; R. Caeiro-Reyb ; m ; Rebeca Reyes-Garcí ; aa ; b ; Beatriz Garcí ; a-Fontanaa ; b ; Jesú ; s Gonzá ; lez-Mací ; asb ; e ; Manuel Muñ ; oz-Torresa ; b ; mmt@mamuto.es" class="auth_mail" title="E-mail the corresponding author
- 关键词：AR ; adequate responders ; IR ; inadequate responders
- 刊名：Maturitas
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：82
- 期：4
- 页码：402-410
- 全文大小：1011 K
文摘
- •
Postmenopausal osteoporosis patients suffer fractures in spite of being on bisphosphonate therapy and with good adherence.
- •
It is unknown whether estradiol and sclerostin circulating levels are associated with inadequate response to bisphosphonate therapy in this population.
- •
Several reports showed that estrogen affect sclerostin production. We observed a nonlinear, inverted U-shaped relation between estradiol and sclerostin levels.
- •
Our findings suggest that increased expression of sclerostin, accompanied by estrogen deficiency, can influence the response to bisphosphonate therapy.